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This analysis shows the economic benefit of antihyper-
tensive treatment in patients 80 years of age or older
from the perspective of the Swiss healthcare system.
The cost-effectiveness analysis of antihypertensive
treatment in the elderly was carried out applying the
results of the Hypertension in the Very Elderly Trial
study to the Swiss healthcare system. The analysis
shows that hypertension treatment provides, compared
with placebo, an additional life expectancy of 0.0457
years per patient, over a follow-up period of 2 years. The
medication cost was covered by the reduction of costs
related to the treatment of strokes, myocardial infarc-
tions and heart failure: the total cost per patient in the
active group resulted in a dominant strategy of savings
compared with the placebo group. Sensitivity analysis
yielded a stable estimate after varying the costs of
medication, stroke, myocardial infarction, heart failure
and life expectancy, confirming the robustness of
these results. Moreover, considering that antihyper-
tensive treatment also positively affects the incidence
of dementia, those net benefits might even be under-
estimated.
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Introduction
Hypertension is a highly prevalent risk factor
for ischaemic heart diseases and stroke world-
wide. The increasing longevity and prevalence of
contributing factors (for example obesity) strongly
affect the morbidity and mortality of cardio-
vascular events in both developed and developing
countries.
1 Therefore, the prevention and manage-
ment of high blood pressure is a major public health
challenge.
In 2004 ischaemic heart diseases caused 40657
deaths in France, 152659 in Germany, 38840 in
Spain and 106142 in the United Kingdom. Stroke-
related deaths were 33487 in France, 68498 in
Germany, 34250 in Spain and 60551 in the United
Kingdom. In Switzerland, the deaths related to
ischaemic heart diseases were about 9200. Half of
the deceased men were older than 80 years and half
of the women were older than 87 years. The deaths
related to stroke were 4083; more than half of them
were 80 years of age or older.
2,3
Several studies of hypertension have observed the
relative risk reduction in total mortality in older and
younger adults, indicating an overall significant
benefit.
4,5 However, Turnbull et al.
6 evidenced the
relative paucity of data for patients over 80 years of
age, even if this group report more than half of the
hypertension-related deaths.
Becket et al.
7 investigated in the ‘Hypertension in
the Very Elderly Trial’ (HYVET) the clinical benefit
of treating patients with hypertension. In a double-
blind, randomized, placebo-controlled, multicenter
clinical trial involving 3845 patients 80 years old or
older, they evaluated the effect of a stepped care
therapy, beginning with 1.5mg indapamide SR
(sustained release) and adding 2–4mg perindopril,
if needed to reach the target blood pressure
(BPp150/80mmHg).
The results of the study provided evidence that
antihypertensive treatment with indapamide SR,
with or without perindopril, in very elderly people
is beneficial: active treatment was associated with a
30% reduction in the rate of fatal or nonfatal stroke
(95% confidence interval (CI),  1 to 51; P¼0.06) and
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JHH JHHOpen ena 39% reduction in the rate of death from stroke
(95% CI, 1 to 62; P¼0.05). The rates of death from
any cause or from cardiovascular causes were also
reduced by 21% (95% CI, 4 to 35; P¼0.02) and 23%
(95% CI,  1 to 40; P¼0.06), respectively. Finally
Becket et al. determined a 64% reduction in the rate
of heart failure in the active-treatment group. Fewer
serious adverse events were reported in the active-
treatment group (358 vs 448 in the placebo group;
P¼0.001). Therefore, it is not too late to start
antihypertensive treatment in very elderly indivi-
duals from a clinical point of view.
In the following study, we estimated the cost-
effectiveness of antihypertensive therapy in patients
80 years of age or older from the perspective of the
Swiss healthcare system.
Materials and methods
Study design
We carried out a retrospective cost-effectiveness
analysis of the HYVET study published by Becket
et al. in May 2008.
7 This double-blind, randomized,
placebo-controlled clinical trial was conducted in
13 countries in Western and Eastern Europe, China,
Australasia and North Africa, and was used as the
basis of efficiency assessment (Table 1).
It was assumed that the effect of antihypertensive
treatment on clinical outcomes could be transferred
to Switzerland. A summary of the effects on clinical
outcomes for the particularly relevant clinical
events is shown in Table 2. The detailed HYVET
protocol has been published extensively.
8
Study end point
The end point of this cost-effectiveness analysis
is the incremental cost per life-year gained in
Switzerland, expressed in Swiss francs (CHF).
Determination of costs and effectiveness
Costs. To determine the total costs of antihyper-
tensive treatment vs placebo, we included four
directly attributable cost groups: (i) the medication
costs according to the dosages used in the HYVET
study, (ii) the acute costs and 2-year follow-up costs
of a myocardial infarction, (iii) the acute costs and
2-year follow-up costs of a stroke and (iv) the costs
of heart failure over 2 years. Indirect costs
(for example costs related to loss of work) and
intangible costs (for example suffering, pain) were
not included. We chose the perspective of third-
party payers in Switzerland.
The costs of treatment with 1.5mg indapamide SR
(Fludex SR tablet, Servier (Suisse) SA, CHF 0.67 per
tablet) and 2–4mg perindopril (Coversum tablet
4mg, Servier (Suisse) SA, CHF 1.00 per tablet) were
based on pharmacy retail prices in Switzerland, as
mainly pharmacies are authorized to sell drugs to
ambulatory patients.
9 The mean daily treatment
costs were calculated on the basis of the reported
treatments in the HYVETstudy: 25.8% of the patient
received 1.5mg indapamide SR alone, 23.9% re-
ceived 1.5mg indapamide SR and 2mg perindopril,
and 49.5% received 1.5mg indapamide SR and 4mg
perindopril. The total drug costs were CHF 420544
per 1000 patients per year, based on a daily
treatment cost of CHF 1.15. The total medication
costs were calculated assuming a patient compli-
ance rate of 100% throughout the treatment period.
Medication costs were calculated for 100% of the
patients, assuming that the acquisition costs also
apply to those patients who no longer take the
medication, and as o12% of patients died during
the observation period. A patient co-payment of
10% was deducted from the pharmacy price.
The costs of an acute myocardial infarction, a
stroke and a heart failure (medication costs, inter-
ventions, hospitalization, outpatient treatment,
rehabilitation) have previously been calculated
and published by international expert groups.
10,11
All costs were adjusted to 2007 values, taking into
Table 1 Design of the HYVET study
Hypothesis Antihypertensive therapy may reduce the risk of
stroke in patients with hypertension who are 80
years of age or older, despite possibly increasing
the risk of death
Study design Randomized, double-blind, placebo-controlled,
multicenter trial in 195 centres in 13 countries in
Western and Eastern Europe, China, Australasia
and North Africa
Inclusion 80 years of age or older
criteria Persistent hypertension (sustained systolic
pressure of 160mmHg)
Exclusion
criteria
Contraindication to use the trial medications,
accelerated hypertension, secondary
hypertension, haemorrhagic stroke in the
previous 6 months, heart failure requiring
treatment with antihypertensive medication,
serum creatinine level 4150mmoll
–1, serum
potassium levelo3.5mmoll
–1, gout, clinical
dementia, requirement of nursing care
Intervention 2 months placebo run-in phase
Active treatment: diuretic indapamide SR
(sustained release, 1.5mg); angiotensin-
converting-enzyme inhibitor, perindopril
(2 or 4mg), if needed to reach target blood
pressure (p150/80mmHg)
Placebo
End point Primary: fatal or nonfatal stroke
Secondary: death from any causes
Period of
observation
2 years
Patients 3845 patients
Active treatment: 1933 patients, average age 83.6
years, 60.7% women, history of cardiovascular
disease 11.5%, smokers 6.4%, diabetes 6.8%,
mean blood pressure while sitting 173.0/
90.8mmHg
Placebo: 1912 patients, average age 83.5 years,
60.3% women, history of cardiovascular disease
12.0%, smokers 6.6%, diabetes 6.9%, mean
blood pressure while sitting 173.0/90.8mmHg
Abbreviation: HYVET, Hypertension in the Very Elderly Trial.
Cost-effectiveness of antihypertensive treatment in elderly
TD Szucs et al
118
Journal of Human Hypertensionaccount inflation in Switzerland. A myocardial
infarction with 2-year follow-up costs CHF 37934,
a stroke with 2-year follow-up accounted for CHF
117729 and 2 years heart failure costs CHF 23173.
To determine the treatment costs that could be
avoided by hypertension therapy, the avoidable
events per 1000 patients over 2 years were taken
from the HYVET study and multiplied by
the treatment costs of each individual treatment
(Table 3). The costs were discounted at 5% per year,
which is the standard rate applied to health care
investments in Switzerland.
12
Effectiveness. In this analysis, the effectiveness
criterion is represented by life-years gained in the
active-treatment group compared with the placebo.
Estimation of the average life expectancy of very
elderly patient with hypertension was based on the
declining exponential approximation of life expec-
tancy (DEALE) method.
13,14 The all-cause mortality
of the Swiss population was adjusted in terms of age
and gender distribution to the HYVET population.
In 2006, the average life expectancy of a 65-year-old
Swiss person was 83.3 years for men and 86.8 years
for women.
15 The remaining life expectancy of
persons with a mean age of 83.6 years is therefore
1.93 years. In the HYVETstudy, the over mortality in
the placebo group was 0.0233 years per patient. This
figure was used as the disease-specific excess
mortality. The combination of the excess mortality
rate and the life expectancy according to the DEALE
method, yielded an adjusted life expectancy results
of 1.84 years.
Cost-effectiveness of hypertension treatment. Costs
per life-year saved (YOLS) were deemed to be
calculated by dividing the discounted cost differ-
ence between active-treatment and placebo group by
the number of life-years gained in the active-
treatment group.
Sensitivity analyses. To test accuracy and sensitiv-
ity of the results (that is, the costs per YOLS), a
sensitivity analysis was carried out. The YOLS, the
hypertension medication costs, and the treatment
costs for stroke, myocardial infarction and heart
failure were varied by ±20%. Threshold analyses
for the most influencing variables were carried out.
Results
Table 3 shows the medication and treatment costs
per 1000 patients over 2 years in the active-
treatment and placebo group. Each patient in the
active-treatment group had an additional medica-
tion cost of CHF 841 over 2 years (1.15 CHF daily),
but also showed a savings potential for the analysed
end points: total costs of stroke, myocardial infarc-
tion and heart failure were CHF 1666 per patient
Table 2 Comparison of treatment effects of the HYVET study
Group Active treatment
(rate per 1000 per year)
Placebo
(rate per 1000 per year)
Unadjusted hazard ratio
(95% confidence interval)
Primary endpoint
Fatal or nonfatal stroke 12.4 17.7 0.70 (0.49–1.01)
Death from stroke 6.5 10.7 0.61 (0.38–0.99)
Secondary endpoint
Death from any cause 47.2 59.6 0.79 (0.65–0.95)
Fatal or non fatal
Any myocardial infarction 2.2 3.1 0.72 (0.30–1.70)
Any heart failure 5.3 14.8 0.36 (0.22–0.58)
Any cardiovascular event 33.7 50.6 0.66 (0.53–0.82)
Abbreviation: HYVET, Hypertension in the Very Elderly Trial.
Table 3 Costs in the treatment and placebo groups per 1000 patients over 2 years
Group Active treatment (CHF) Placebo (CHF) Difference (CHF)
Medication cost 841087 0 841087
Cost of stroke 1459838 2083801  623963
Cost of myocardial infarction 83455 117595  34141
Cost of heart failure 122817 342962  220145
Total costs per 1000 patients 2507197 2544359  37162
Discounted at 5% per year  35392
Abbreviation: CHF, Swiss francs.
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patient were CHF 2544. Thus, the total cost
difference in favour of treatment group is nominal
CHF 37 per patient per 2 year (discounted: CHF 35).
The effectiveness calculation yielded an addi-
tional life expectancy of 0.0457 years in the active-
treatment group compared with the placebo group
over a period of 2 years (Table 4).
This analysis resulted in a net cost savings, and
hence a ratio of costs per YOLS is not required.
The sensitivity analysis (Figure 1) shows that the
factors that mostly contribute to the costs variability
are medication, stroke and heart failure costs. In
case of a 20% increase of drug costs, the treatment
would result in a cost-effectiveness of CHF 2734 per
YOLS. In contrast, a 20% decrease results in a net
benefit of CHF 4284. To reach the threshold for
stroke and heart failure, it would be necessary to
reduce their cost of 6.0% and 16.9%, respectively.
That means the stroke and heart failure cost over a
period of 2 years should be reduced by CHF 7012
and CHF 3912, respectively. A hypothetical increase
of 20% of the stroke costs results in a cost saving of
CHF 3378 (a dominant strategy). On the other side, a
20% reduction results in a cost-effectiveness of CHF
1828 per YOLS.
Discussion
The HYVET study was stopped prematurely,
after 140 strokes for ethical reason; the active-
treatment group already showed evidence of a
reduction in the rate of the primary and secondary
end points. Despite this anticipated stop, the
economic assessment of antihypertensive treatment
in patients 80 years of age or older has shown that
the administration of the diuretic indapamide SR
and, if necessary, of the angiotensin-converting-
enzyme inhibitor, perindopril, is cost-effective.
The benefits are primarily attributed to the preven-
tion of stroke and heart failure.
The incremental life expectancy of 0.0457 years
(about 16–17 days) looks relatively small. However,
as emphasized by Wright et al.
16, the gain in life
expectancy should be compared with gains
from other interventions aimed at the same target
population.
Unfortunately, strict comparison with other stu-
dies is difficult, as cost-effectiveness analyses of
hypertension treatment usually include younger
patients, or are based on country-specific situations.
For example, the cost-effectiveness analyses of
losartan (an angiotensin type 1 receptor blocker) in
Table 4 Expected additional life expectancy due to hypertension treatment
Average age of patients at baseline in the HYVET study
Active-treatment group 83.6 years
Placebo group 83.5 years
Normal life expectancy of a 65-year-old Swiss person
Men 83.3 years
Women 86.8 years
Life expectancy study population (60% women) 1.93 years
Mortality rate per patient year 0.0233
Expected fatal cases in placebo group 59.6 per 1000 patients per year
Disease-specific mortality rate per year 0.0233
Adjusted mortality
Adjusted average mortality (DEALE) 0.0239
Remaining life expectancy (DEALE) 1.841 years
Expected fatal events in 2 years
Active-treatment group 94.4 per 1000 patients
Placebo group 119.2 per 1000 patients
Cases prevented 24.8 per 1000 patients
Years of life saved (YOLS) per 1000 patients (prevented cases per 1000
patients per remaining life expectancy)
24.8 1.841¼45.66 years
Incremental life expectancy of hypertension treatment in comparison to placebo 0.0457 years per patient
Abbreviations: DEALE, declining exponential approximation of life expectancy; HYVET, Hypertension in the Very Elderly Trial.
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Figure 1 Sensitivity analysis. CHF, Swiss francs; YOLS, years of
life saved; HF, heart failure; MI, myocardial infarction.
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hypertrophy based on the results of the LIFE study,
17
reported an incremental life expectancy of 0.0495
years (about 18 days) and a potential cost-savings of
CHF 24 in Switzerland, and a cost-effectiveness of
864 h (1380 CHF), 4188 h (6689 CHF), 3195 h (5103
CHF) and 1337 Can $ (1347 CHF) per life-year saved
in the Netherlands, Sweden, UK and Canada,
respectively.
18–22 However, the average age in the
LIFE study was 66.9 years, with all patients between
55 and 80 years of age.
In another study, Tsevat et al.
23 have estimated
that 35 years old men with hypertension would gain
1.1–5.3 years (13–64 months) by reducing their
diastolic blood pressure to 88mmHg. For 35 years
old women the incremental life expectancy would
be 0.9–5.7 years (11–68 months).
In a more recent analysis, Gandjour et al.
24 have
estimated that antihypertensive treatment of 60–69
years old individuals would result in 0.2–0.6 life-
years (2–7 months) gained for men and 0.1–0.6 life-
years (1–7 months) for women.
It should be mentioned that the HYVETstudy also
included an assessment of cognitive function, as
earlier observational studies have shown a positive
association between hypertension and incidence of
dementia.
25–32 In this substudy,
33 Peters et al.
reported a trend for a positive influence of the
active treatment on the incidence of cognitive
function and dementia (with a hazard ratio of 0.86,
95% CI 0.67–1.09). As the study was stopped
prematurely and because the follow-up period was
short, this finding was not significant. Nevertheless,
Peters et al. combined their results with other
placebo-controlled trial of antihypertensive treat-
ment in a meta-analysis, in which they could
observe a significant risk reduction in treated
patients (hazard ratio 0.87, 95% CI 0.76–1.00,
P¼0.045).
In this cost-effectiveness analysis, we decided not
to include the effects of antihypertensive treatment
on dementia incidence, as they were not significant
in the HYVET per se. However, it is necessary to
mention that the monetary and psychological costs
of caring for people with dementia are very high.
34,35
Thus, the net savings of antihypertensive treatment
in this population might be even more favourable
and might be underestimated in this analysis,
respectively.
In this analysis, we also excluded the costs of
adverse events, which were significantly lower in
the active-treatment group of the HYVET study
(P¼0.001). However, it should be considered that
such costs would speak even more in favour for
active treatment.
A limitation of the HYVET study, and conse-
quently of this cost-effectiveness analysis, is the
absence of data related to diabetes and renal failure.
These diseases strongly influence the quality of life
of the affected persons,
36 are highly prevalent in the
elderly and are quite expensive, as reported, for
example, by Mullins et al. in their comparison of
hypertension-related costs from multinational clin-
ical studies.
37,38
Another limitation of this analysis is that the
HYVET study implicitly assumed a homogeneous
population across the countries participating in the
study. But the study was conducted in 13 countries
that partially strongly differ between each other in
demographics characteristics (for example age dis-
tribution, ethnic composition, life style and so on),
health care system, risk factors prevalence, and
quality of diagnoses, treatment and monitoring. The
results of the HYVET study were transferred into a
Swiss context, using country-specific demographic
rates and health care costs, but it was not possible to
adjust the analysis for all differences between the
Swiss and the original study population. In addi-
tion, it should not be forgotten that the HYVETstudy
population is only partly representative for a total
collective of hypertensive patients, as there were
well-defined exclusion criteria. An additional lim-
itation is that the HYVETstudy did not include data
on the quality of life of the patients and on
respective rehabilitation measures.
A last limitation of this analysis is the assumption
of a 100% compliance of drug treatment.
The demography of our society is changing as fast
as never before. In the last few decades the mean life
expectancy has strongly grown up. The actual
standards of study design, which seems to prefer-
ably include patient below 80 years of age, are
becoming obsolete. New and more studies are
needed to analyse the cost-effectiveness of medica-
tion in very elderly people.
In conclusion, the antihypertensive treatment of
very elderly persons, on the basis of the HYVET
study and performed from a Swiss perspective,
reduced the stroke and heart failure incidence,
increasing the life expectancy by 0.0457 years per
patient and resulting to be net cost-saving, that is,
reflecting a dominant strategy.
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What is known about the topic
K Hypertension is a highly prevalent risk factor for ischaemic
heart diseases and stroke worldwide, and the increasing
longevity and prevalence of contributing factors (for
example obesity) strongly affect the morbidity and mortality
of cardiovascular events. The prevention and manage-
ment of high blood pressure is a major public health
challenge.
K Antihypertensive treatment reduces the relative risk of total
mortality indicating an overall significant benefit.
K The actual standards of study design seem to preferably
include patient below 80 years of age.
What this study adds
K Antihypertensive treatment shows benefits also in very
elderly persons (80 years of age or older).
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